AHAlan R. Hounsell

Alan R. Hounsell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alan R. Hounsell has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations of Periprostatic Adipose Tissue Measures Obtained after Androgen Deprivation Therapy with Prostate Tumor Aggressiveness and Gene Expression Profiles

    by Sarah J. Winter, Suneil Jain, Gillian Prue, Michelle Leech, Alan R. Hounsell, Conor K. McGarry, Emma H. Allott

    Background: Higher periprostatic adipose tissue (PPAT) quantity has been associated with increased prostate cancer aggressiveness. However, PPAT definitions vary between studies, and few have examined associations of PPAT with tumor biology. Methods: Using radiation-planning computed tomography scans from 316 patients with prostate cancer treated with androgen deprivation therapy at the Northern Ireland Cancer Centre, we contoured PPAT according to three anatomic definitions. Associations of adipose tissue quantity and density (continuous measures and tertiles) with disease aggressiveness (Gleason grade ≥4 + 3 vs. ≤3 + 4) were examined using logistic regression. Exploratory gene set enrichment analysis identified PPAT-associated pathways enriched in prostate tumors. Results: Among men with prostate cancer, an elevated total quantity of pelvic adipose tissue [T3 vs. T1 fully adjusted odds ratio (OR), 1.97; 95% confidence interval (CI), 1.10–3.56] and higher density of PPAT in closest proximity to the prostate (T3 vs. T1 fully adjusted OR, 2.36; 95% CI, 1.00–5.68) were associated with increased odds of high-grade disease. Higher waist circumference was also associated with increased tumor aggressiveness (T3 vs. T1 fully adjusted OR, 1.99; 95% CI, 1.04–3.86). Men with a higher quantity of total pelvic adipose tissue had enriched glucose and lipid signaling-related pathways in their tumors. Conclusions: Greater total pelvic adipose tissue quantity and higher PPAT density were associated with increased tumor aggressiveness among men with prostate cancer. Exploratory analyses identified tumor glucose and lipid metabolism as potential contributing mechanisms. Impact: Our findings support a potential role for PPAT in prostate cancer aggressiveness. Associations of increased PPAT density with higher tumor grade and of a higher quantity of pelvic fat with enhanced tumor glucose and lipid signaling suggest potential contributing mechanisms to be explored in future studies.

  • A systematic review of the dosimetric consequences of the interplay effect

    by Asmaa M. Ali, Jason B. Greenwood, Alan Hounsell, Conor McGarry


  • Open Access

    Evaluation of tumour motion and internal/external correlation in lung SABR

    by Asmaa M Ali, Jason B Greenwood, Gerard M Walls, Louise Belshaw, Christina E Agnew, Jonathan McAleese, Glenn Whitten, Denise M Irvine, Alan R Hounsell, Conor K McGarry

    Objective: This study aims to analyse lung tumour motion and to investigate the correlation between the internal tumour motion acquired from four-dimensional computed tomography (4DCT) and the motion of an external surrogate. Methods: A data set of 363 4DCT images was analysed. Tumours were classified based on their anatomical lobes. The recorded gross tumour volume (GTV) information included the centroid GTV motion in the superior–inferior, anteroposterior and left-right directions, and in three-dimensions (3D). For the internal/external correlation, the RPM surrogate breathing signals of 260 patients were analysed via an in-house script. The external motion was correlated with the 3D centroid motion, and the maximum tumour motion via Spearman’s correlation. The effect of tumour volume on the amount of motion was evaluated. Results: The greatest 3D tumour amplitude was found for tumours located in the lower part of the lung, with a maximum of 26.7 mm. The Spearman’s correlation of the internal 3D motion was weak in the upper (r = 0.21) and moderate in the middle (r = 0.51) and the lower (r = 0.52) lobes. There was no obvious difference in the correlation coefficients between the maximum tumour displacement and the centroid motion. No correlation was found between the tumour volume and the magnitude of motion. Conclusion: Our results suggest that tumour location can be a good predictor of its motion. However, tumour size is a poor predictor of the motion. Advances in knowledge: This knowledge of the distribution of tumour motion throughout the thoracic regions will be valuable to research groups investigating the refinement of motion management strategies.


  • Open Access

    Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: Results from the NI-HEART study

    by Gerard M. Walls, John O'COnnor, Mark Harbinson, Eamon P. McCarron, Frances Duane, Conor McCann, Peter McKavanagh, David I. Johnston, Jayaraj Erekkath, Valentina Giacometti, et al.


  • Open Access

    In vivo dosimetry in pelvic brachytherapy

    by Orla Anne Houlihan, Geraldine Workman, Alan R Hounsell, Kevin M Prise, Suneil Jain

    Brachytherapy is an effective treatment in the curative management of prostate and gynaecological cancers. With advances in technology, brachytherapy has increased in complexity in recent years. Human error, equipment malfunction, patient organ motion and radioactive source displacement can result in substantial deviation of delivered dose from planned dose. To limit adverse clinical outcomes, adequate steps to improve the robustness of pathway processes, ensure the implementation of appropriate treatment margins and confirm the delivered dose must be considered. In vivo dosimetry is one such method of dose validation which, if implemented appropriately within clinical practice, is an attractive technique for reducing dosimetric uncertainties and identifying potential errors. This review aims to describe the dosimetric uncertainties and potential errors associated with brachytherapy, the potential for in vivo dosimetry in adaptive brachytherapy as a key method of dose validation, and the clinical considerations and future directions of in vivo dosimetry. Advances in knowledge: This paper describes the potential role for in vivo dosimetry in the reduction of uncertainties in pelvic brachytherapy, the pertinent factors for consideration in clinical practice, and the future potential for in vivo dosimetry in the personalisation of brachytherapy.


  • Open Access

    Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging

    by Sarah O. S. Osman, Emily Russell, Raymond B. King, Karen Crowther, Suneil Jain, Cormac McGrath, Alan R. Hounsell, Kevin M. Prise, Conor K. McGarry

    Background: In this study, a novel pelvic phantom was developed and used to assess the visibility and presence of artefacts from different types of commercial fiducial markers (FMs) on multi-modality imaging relevant to prostate cancer.Methods and materials: The phantom was designed with 3D printed hollow cubes in the centre. These cubes were filled with gel to mimic the prostate gland and two parallel PVC rods were used to mimic bones in the pelvic region. Each cube was filled with gelatine and three unique FMs were positioned with a clinically-relevant spatial distribution. The FMs investigated were; Gold Marker (GM) CIVCO, GM RiverPoint, GM Gold Anchor (GA) line and ball shape, and polymer marker (PM) from CIVCO. The phantom was scanned using several imaging modalities typically used to image prostate cancer patients; MRI, CT, CBCT, planar kV-pair, ExacTrac, 6MV, 2.5MV and integrated EPID imaging. The visibility of the markers and any observed artefacts in the phantom were compared to in-vivo scans of prostate cancer patients with FMs.Results: All GMs were visible in volumetric scans, however, they also had the most visible artefacts on CT and CBCT scans, with the magnitude of artefacts increasing with FM size. PM FMs had the least visible artefacts in volumetric scans but they were not visible on portal images and had poor visibility on lateral kV images. The smallest diameter GMs (GA) were the most difficult GMs to identify on lateral kV images.Conclusion: The choice between different FMs is also dependent on the adopted IGRT strategy. PM was found to be superior to investigated gold markers in the most commonly used modalities in the management of prostate cancer; CT, CBCT and MRI imaging.


  • The Challenge Facing Academic Radiotherapy Physics in the UK

    by A.R. Hounsell, M.A. Hawkins, P. Evans


  • Open Access

    Small field dosimetry for the small animal radiotherapy research platform (SARRP)

    by Mihaela Ghita, Stephen J. McMahon, Hannah F. Thompson, Conor K. McGarry, Raymond King, Sarah O. S. Osman, Jonathan L. Kane, Amanda Tulk, Giuseppe Schettino, Karl T. Butterworth, et al.

    Preclinical radiation biology has become increasingly sophisticated due to the implementation of advanced small animal image guided radiation platforms into laboratory investigation. These small animal radiotherapy devices enable state-of-the-art image guided therapy (IGRT) research to be performed by combining high-resolution cone beam computed tomography (CBCT) imaging with an isocentric irradiation system. Such platforms are capable of replicating modern clinical systems similar to those that integrate a linear accelerator with on-board CBCT image guidance. In this study, we present a dosimetric evaluation of the small animal radiotherapy research platform (SARRP, Xstrahl Inc.) focusing on small field dosimetry. Physical dosimetry was assessed using ion chamber for calibration and radiochromic film, investigating the impact of beam focus size on the dose rate output as well as beam characteristics (beam shape and penumbra). Two film analysis tools) have been used to assess the dose output using the 0.5 mm diameter aperture. Good agreement (between 1.7–3%) was found between the measured physical doses and the data provided by Xstrahl for all apertures used. Furthermore, all small field dosimetry data are in good agreement for both film reading methods and with our Monte Carlo simulations for both focal spot sizes. Furthermore, the small focal spot has been shown to produce a more homogenous beam with more stable penumbra over time. FilmQA Pro is a suitable tool for small field dosimetry, with a sufficiently small sampling area (0.1 mm) to ensure an accurate measurement. The electron beam focus should be chosen with care as this can potentially impact on beam stability and reproducibility.


  • Impact and practical aspects of rectal spacer insertion for prostate stereotactic radiotherapy – First UK experience

    by Ciaran Fairmichael, Raymond B. King, Sara Os. Osman, Denise M. Irvine, Alan R. Hounsell, Darren M. Mitchell, Conor K. McGarry, Suneil Jain

  • Open Access

    A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy

    by Ciara A. Lyons, Raymond B. King, Sarah O.S. Osman, Stephen J. McMahon, Joe M. O’sullivan, Alan R. Hounsell, Suneil Jain, Conor K. McGarry

    Traditional CTV-PTV margin recipes are not generally applicable in the situation of stereotactic ablative radiotherapy (SABR) treatments of multiple target volumes with a single isocentre. In this work, we present a novel geometric method of margin derivation based on CBCT-derived anatomical data. Twenty patients with high-risk localized prostate cancer were selected for retrospective review. Individual volumes of interest (prostate, prostate and seminal vesicles and pelvic lymph nodes) were delineated on five representative CBCTs and registered to the planning CT using two registration protocols: bone match or prostate-based soft tissue match. Margins were incrementally expanded around composite CTV structures until 95% overlap was achieved. CTV-PTV margins of 5.2, 6.5 and 7.6 mm were required for prostate, prostate and seminal vesicles and pelvic lymph nodes respectively using a prostate matching protocol. For the prostate and seminal vesicle structures, margins calculated using our method displayed good agreement with a conventional margin recipe (within ±1.0 mm). We have presented an alternative method of CTV-PTV margin derivation that is applicable to SABR treatments with more than one isocentric target. These results have informed an institutional trial of prostate and pelvic nodal SABR in men with high-risk localized prostate cancer.